Navigation Links
Pharmion and MethylGene Initiate Phase One Combination Clinical Trial with MGCD0103 and Taxotere(R) in Patients with Solid Tumors
Date:10/10/2007

BOULDER, Colo. and MONTREAL, Oct. 10 /PRNewswire-FirstCall/ -- Pharmion Corporation (Nasdaq: PHRM) and MethylGene Inc. (TSX: MYG) today announced the initiation of a Phase One clinical trial evaluating MGCD0103, the Companies' isotype-selective histone deacetylase inhibitor (HDACi) product candidate, in combination with Taxotere(R) (docetaxel; Sanofi Aventis) in patients with solid tumors. Taxotere is an approved chemotherapy agent marketed for use in breast, lung, prostate, gastric and head and neck cancer.

In the first portion of the trial, MGCD0103 will be given orally, three times per week for three weeks in combination with Taxotere, which will be administered on Day 1 of each three-week cycle to patients with cancer where treatment with Taxotere is approved or considered standard of care, or patients who have no available standard of care therapeutic options. Key objectives for this portion of the study will be threefold: to evaluate the safety of administering these two agents together; determine the maximum tolerated dose of MGCD0103 when combined with the two fixed doses of Taxotere; and to define optimal dosing for the second portion of the trial. In the second portion of the trial, objectives include further assessment of the safety of the drug combination, quantification of tumor responses and measurement of the pharmacodynamic and pharmacokinetic characteristics. The trial may enroll up to 50 patients at cancer centers in North America. The trial is expected to take 12 to 18 months to complete.

"This is an important step forward in the clinical development of MGCD0103," said Andrew Allen, executive vice president and chief medical officer of Pharmion Corporation. "Cytotoxic chemotherapies such
'/>"/>

SOURCE Pharmion Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Pharmions Amrubicin Shows Encouraging Results Compared to Standard of Care in Second Line Treatment of Small Cell Lung Cancer
2. Pharmion to Present Clinical Data on Commercial and Pipeline Products at 2007 American Society of Clinical Oncology (ASCO) Meeting
3. Malvern initiates European user group meetings for chemical imaging
4. Protalix BioTherapeutics, Inc. Receives Approval from the FDA to Initiate a Phase III Clinical Trial of prGCD
5. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
6. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
7. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
11. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... -- Echo Therapeutics, Inc. (Nasdaq: ECTE ) ... CGM System as a non-invasive, wireless continuous glucose ... Doman , Executive Chairman and Interim CEO of ... Capital Markets, Tenth Annual Equity Conference. ... to prospective corporate partners and investors at 9:00 ...
(Date:1/15/2014)... NEW YORK , Jan. 15, 2014 ... market research report is available in its ... Dermatitis - India Drug Forecast and Market ... PharmaPoint: Atopic Dermatitis - ... 2022 Summary,Although the past decade ...
(Date:1/15/2014)... 15, 2014  Zafgen, Inc., a leading biopharmaceutical ... severely obese patients, today announced initial results from ... inhibitor of methionine aminopeptidase 2 (MetAP2), in patients ... genetic obesity.  These results showed improvements in body ... in body fat content and preserved lean body ...
Breaking Medicine Technology:Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4
... CUPERTINO, Calif. , July 1 DURECT Corporation (Nasdaq: DRRX ... which it may sell up to $50 million of its registered ... is not obligated to utilize any of the $50 million facility. ... this facility. , , , ...
... /PRNewswire-Asia-FirstCall/ -- Dehaier Medical Systems Ltd.,(Nasdaq: DHRM ), an emerging ... medical products in China , said today,that Rita Zheng Liu ... will present at the Global Hunter,Securities 2010 China Conference to be held ... , , ...
Cached Medicine Technology:DURECT Corporation Secures $50 Million Committed Equity Financing Facility 2DURECT Corporation Secures $50 Million Committed Equity Financing Facility 3Dehaier Medical Systems to Present to Investors at Global Hunter Securities 2010 China Investor Conference in San Francisco 2Dehaier Medical Systems to Present to Investors at Global Hunter Securities 2010 China Investor Conference in San Francisco 3
(Date:4/14/2014)... orphaned by HIV/AIDS in South Africa may provide insight ... behavior issues in other areas of the world, which ... that could lead to successful interventions. , A ... United Nations mentions that due to the HIV/AIDS pandemic, ... African, children are at an increased risk for mental ...
(Date:4/14/2014)... A new study shows that moderate to severe ... risk of stroke, cancer and death. , Results of ... to severe obstructive sleep apnea were four times more ... times more likely to have a stroke (HR = ... (HR = 3.4), and 2.5 times more likely to ...
(Date:4/14/2014)... Dallas study involving serious youth offenders, the answer to one ... seven years: "How long do you think you,ll live?", According ... offending over time., Author Dr. Alex Piquero said the study ... of them offend at very high rates and commit more ... much later in life offend much less., "In a lot ...
(Date:4/14/2014)... with symptoms increasing dramatically during some of the most important ... has found. , Depressive symptoms increased on average by 68 ... young men, who were around 25 years old when they ... their children. The results of the study were published April ... is the first to identify when young fathers are at ...
(Date:4/14/2014)... Lower weight babies and babies who aren,t breastfed ... risk of developing chronic inflammation and related health ... study. , "There were good reasons to hypothesize ... inflammation in adulthood," says Thomas McDade (Northwestern University), ... in the Child & Brain Development program. "It ...
Breaking Medicine News(10 mins):Health News:Researchers identify children with emotional behavior difficulties 2Health News:Researchers identify children with emotional behavior difficulties 3Health News:Study links severe sleep apnea to increased risk of stroke, cancer and death 2Health News:UT Dallas study: Youth who fail to envision future commit more crimes 2Health News:Young dads at high risk of depression, too 2Health News:Low birth weight, less breastfeeding create later health risks 2
... similar medicines pose big stomach risks, study notes ... of patients don,t tell their doctors that they take ... potentially dangerous omission, a new study has found. , ... medicine intake, it is no wonder that adverse events ...
... four out of ten HIV positive African-American men could be putting ... in the latest UK-based Journal of Advanced Nursing. , A ... that many of the 40 to 65 year-olds were engaging in ... oral sex, with 25 per cent having unprotected vaginal sex and ...
... contribute to heart attack, stroke and dementia, likely also ... researchers say. , Homocysteine levels rise when folic acid ... are often poor in folate-rich fruits, tomatoes, vegetables and ... the Medical College of Georgia. , Scientists want to ...
... Donates Hotel Points to Benefit More Transplant Patients and Family ... ... The National Foundation for,Transplants (NFT) announced today that it will extend free ... to,pre- and post-transplant care through an expansion of its Home Away From,Home ...
... Winners Announced at Annual ASRM Meeting, ... won Ferring,Pharmaceuticals, national 2007 My Little Miracle ... the births of their ,little miracles,children born ... fertility treatments.,The fourth annual contest celebrated the ...
... Oct. 15 Edwards Lifesciences,Corporation (NYSE: EW ), ... cardiovascular disease, plans to announce its operating,results for the ... on,Monday, October 22, 2007 and will host a conference ... results. To participate in the conference call, dial ...
Cached Medicine News:Health News:Many Patients Don't Report Use of OTC Pain Drugs 2Health News:Many Patients Don't Report Use of OTC Pain Drugs 3Health News:Older African-American men with HIV often have sex without condoms 2Health News:Impact of elevated homocysteine levels on vision under study 2Health News:Impact of elevated homocysteine levels on vision under study 3Health News:National Foundation for Transplants to Expand Program Providing Hotel Accommodations to Patient Families 2Health News:National Foundation for Transplants to Expand Program Providing Hotel Accommodations to Patient Families 3Health News:Ferring Announces $10,000 Grand Prize Winner of 2007 My Little Miracle Essay Contest 2Health News:Ferring Announces $10,000 Grand Prize Winner of 2007 My Little Miracle Essay Contest 3Health News:Ferring Announces $10,000 Grand Prize Winner of 2007 My Little Miracle Essay Contest 4Health News:Edwards Lifesciences to Host Earnings Conference Call on October 22, 2007 2
Immuno-turbidimetric assay for Free Protein Sby STA© Analyzers. Suspension of microparticles coated with monoclonal antibodies to Free Protein S....
Colorimetric Assay of Unfractionated and Low Molecular Weight Heparins by STA© Analyzers. Lyophilized, patent-pending chromogenic substate, CBS 52.44 of ~4.2 moles/vial and bovine factor Xa ~1.1...
Substrate Plasma for Factor VII Assay by STA© Analyzers. Freeze-dried human plasma from which factor VII has been removed by selective immuno-adsorption....
Substrate Plasma for Factor IX Assay by STA© Analyzers. Freeze-dried human plasma from which factor IX has been removed by selective immuno-adsorption....
Medicine Products: